DALLAS / Oct 17, 2024 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice provider, today announced its recognition by the Institute for Healthcare Improvement (IHI) as an Age-Friendly Health Systems Participant.
Age-friendly Health Systems Participants are recognized for being on the journey to becoming an Age-Friendly Health System and have submitted a description of how they are putting four essential elements of care--the 4Ms--into practice with older patients.
"We're participating in this vital movement to share our practices and learn from others providing Age-Friendly Care," said Bud Langham, executive vice president of clinical excellence & strategy at Enhabit. "This initiative aligns with our vision to provide the best possible care for every older adult."
As part of the Age-Friendly Health Systems initiative, The John A. Hartford Foundation and the Institute for Healthcare Improvement, in partnership with the American Hospital Association and the Catholic Health Association of the United States, are helping hospitals and other care settings, such as home-based care, implement a set of evidence-based interventions specifically designed to improve care for older adults. These interventions focus on the 4Ms:
Enhabit joins a select number of health care systems worldwide, working to tailor care to patients' goals and preferences.
About Enhabit Home Health & Hospice
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 256 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
Last Trade: | US$7.91 |
Daily Change: | 0.31 4.08 |
Daily Volume: | 502,424 |
Market Cap: | US$397.710M |
November 06, 2024 August 06, 2024 July 01, 2024 May 08, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB